By Assoc. Prof. Dr. Mehmet Sorar | Published: 01.02.2025
Parkinson Plus Treatment Doctor: How to Choose, What to Ask
Neurology is the natural place to start with Parkinson Plus: the NHS says a neurologist diagnoses multiple system atrophy (MSA) from the symptoms. These conditions need a team more than a single doctor. When choosing, look at which criteria the diagnosis rests on, whether the evidence is described openly and how you reach the rest of the team. This page ranks and recommends no one; it offers questions.
Which kind of doctor do you start with?
The first appointment is usually with a neurologist, and later care involves several disciplines. For progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), Lamb and colleagues list neurology, physiotherapy, occupational therapy, speech and language therapy, dietetics, ophthalmology, psychology and palliative care. The same review does not list deep brain stimulation or transcranial magnetic stimulation (TMS) among established options.
This guide says nothing about any doctor's experience, case numbers or results, and it ranks no doctor, clinic or city. What follows are points you can check yourself. The NHS says MSA is diagnosed partly from how long symptoms have lasted and how quickly they worsen, so it helps to bring a note of when each symptom began and how it changed.
Which criteria should the diagnosis rest on?
Each condition has internationally recognised criteria, and you can ask which one the doctor used. They sort a diagnosis made in life into categories. Those categories show how sure the diagnosis is, not how advanced the disease is.
| Condition | Criteria | Categories and notes |
|---|---|---|
| MSA | Movement Disorder Society criteria, 2022 (Wenning and colleagues) | Neuropathologically established, clinically established (needs brain MRI findings suggestive of MSA), clinically probable, and possible prodromal MSA (a research category for the earliest stage). The authors say the criteria still need validation in a prospective clinical study. |
| PSP | Movement Disorder Society criteria, 2017 (Hoglinger and colleagues) | Four functional areas (eye movement, postural instability, akinesia, thinking) combine into probable PSP, possible PSP and suggestive of PSP. A definite diagnosis rests on examination of brain tissue. |
| CBD | Criteria of Armstrong and colleagues, 2013 | Built from 267 cases confirmed by examination of brain tissue. Describes clinical types including corticobasal syndrome, plus probable CBD (a research criterion) and the broader possible CBD. The authors say validation is needed. |
| DLB | Fourth consensus report of the DLB Consortium, 2017 (McKeith and colleagues) | Clinical features are separated from diagnostic biomarkers. More weight is given to REM sleep behaviour disorder and to a heart scan called MIBG scintigraphy. |
Knowing the limits helps you read words such as "probable" or "possible". Wenning and colleagues say the new MSA criteria replaced earlier consensus criteria that lacked sensitivity for early disease. The "clinically established" category aims for the highest specificity, meaning few wrong diagnoses, and "clinically probable" gives higher sensitivity, meaning more early cases are caught. For PSP, Hoglinger and colleagues say supportive clues and imaging are not defining, and the abstract gives no numbers for sensitivity or specificity. The older 1996 PSP criteria were highly specific but missed forms other than Richardson syndrome.
For DLB, McKeith and colleagues name supporting imaging findings: reduced dopamine transporter uptake on a FP-CIT SPECT scan, low activity at the back of the brain on FDG-PET with a pattern called the cingulate island sign, and relatively preserved volume of the inner temporal lobe on MRI. They add that management advice is largely expert opinion because few randomised trials exist. For CBD, Armstrong and colleagues explain that corticobasal syndrome is a clinical label, while CBD refers to the brain changes, so a person given the label does not necessarily have CBD. The conditions are described on What is Parkinson Plus, early symptoms and daily life.
What can you ask at the first appointment?
You can ask for the diagnosis and its certainty to be explained in plain words. The aim of the questions below is to clarify the conversation, not to test the doctor.
- Which condition is suspected, and in which category: established, probable or possible?
- Which criteria was the diagnosis based on, and which scans or tests were used?
- How were Parkinson's disease and other causes ruled out?
- Which symptom will be treated with what, and how will the benefit of medicines be tracked?
- How will you reach physiotherapy, speech and language therapy, occupational therapy, dietetics, eye care and palliative care?
- Which medicines could make symptoms worse? Lamb and colleagues say most antipsychotics can worsen parkinsonism.
- If TMS or deep brain stimulation is suggested, which study supports it and how strong is the evidence?
Which problems call for which referral?
Care follows the symptoms, so referrals do too. Problems and specialists pair up as follows:
- swallowing and communication: speech and language therapy (NHS, MSA)
- movement and daily tasks: physiotherapy and occupational therapy (NHS, MSA)
- eye and eyelid problems: eye care, with botulinum toxin one option for eyelid spasm (Lamb and colleagues)
- nutrition: dietetics (Lamb and colleagues)
- mood: psychology and antidepressants, though Lamb and colleagues say antidepressants are often poorly tolerated
- dizziness and sleep problems: medicines (NHS, MSA)
- comfort and support: palliative care (Lamb and colleagues)
Which statements deserve a careful question?
Some statements conflict with the published evidence, and they deserve a question. Lamb and colleagues say there is no disease-modifying treatment (one that changes the course of the disease) for PSP or CBD and no approved drug reliably controls symptoms. The NHS says no treatment stops MSA getting worse. So it is fair to ask about:
- any method said to stop, reverse or fully solve the condition
- TMS or deep brain stimulation described as an established treatment for these conditions
- a claim that the diagnosis is completely certain during life; Hoglinger and colleagues say a definite PSP diagnosis rests on examination of brain tissue, and Wenning and colleagues say the MSA criteria are still being validated
Lamb and colleagues also say most recommendations for PSP and CBD come from other conditions, case series or expert opinion. When a medicine is suggested, ask what it rests on: experience in another condition, a case series or expert opinion. Levodopa gives a small, short-lived benefit in many cases, and a poor response is part of the diagnostic picture. You can expect the doctor to say how long a trial will last and how it will be judged. The steps of care are set out on Parkinson Plus treatment, the care process, and a guide for a family with a new diagnosis is on Parkinson Plus syndrome, a map for the journey.
When should you not wait for an appointment?
Fainting, a serious fall, choking when swallowing, or a cough with fever and breathlessness needs medical attention without waiting for an appointment date. The NHS lists dizziness or fainting among MSA symptoms. If a new problem appears and you are unsure whether it belongs to the condition, contact the care team or an emergency service. For choking that will not clear or severe breathlessness, call emergency services straight away. The wider picture of the group is on Overview of Parkinson Plus disease.
Sources
- Wenning and colleagues, The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy (2022)
- Hoglinger and colleagues, Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria (2017)
- Armstrong and colleagues, Criteria for the diagnosis of corticobasal degeneration (2013)
- McKeith and colleagues, Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium (2017)
- Lamb and colleagues, Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options (2016)
- NHS: Multiple system atrophy (MSA)
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: Parkinson Plus